- The U.S. District Court for the Northern District of West Virginia denies a motion by Mylan (NASDAQ:MYL) and affirms the FDA's decision recognizing Teva's (NYSE:TEVA) 180-day "first-to-file" exclusivity for generic Celebrex 100, 200 and 400 mg capsules.
- Teva and Celebrex maker Pfizer (NYSE:PFE) reached a settlement on April 17 regarding Teva's generic version which it plans to launch in December of this year. According to IMS, the branded product generated $2.2B in U.S. sales in 2013.